<DOC>
	<DOCNO>NCT00643643</DOCNO>
	<brief_summary>To investigate relationship pharmacokinetics pharmacodynamics UK-427,857 antiviral effect patient human immunodeficiency virus ( HIV ) .</brief_summary>
	<brief_title>Pharmacokinetics , Pharmacodynamics , And Safety Of Maraviroc ( UK-427,857 ) In Patients With Human Immunodeficiency Virus</brief_title>
	<detailed_description />
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Maraviroc</mesh_term>
	<criteria>Inclusion criterion : Male HIV surgically sterilize female HIV showing symptom HIV Weight 50 90kg within permit range height Exclusion criterion : Subjects CD4 count le 250cells/mm3 HIV viral load less 5000 copies/mL Subjects acquire immune deficiency syndrome ( AIDS ) previous AIDS diagnosis Subjects whose HIV infection diagnose less 3 month prior screen , evidence recent seroconversion Subjects take antiretroviral drug eight week prior study screen visit</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>November 2010</verification_date>
	<keyword>HIV</keyword>
	<keyword>Treatment Na√Øve</keyword>
</DOC>